Patrick Lamy, Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO), sold 5,000 shares at $57.03 ($285K) on 2025-01-27, disclosed to the SEC on 2025-01-29.
Scheduled sale ($285k) by Senior VP, Commercial Strategy under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| AKRO | SELL | 2025-06-20 | $108K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $50K | — | Filing → |
| AKRO | SELL | 2025-06-04 | $201K | — | Filing → |